Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. (Tables)

12 Months Ended

Dec. 31, 2019

Acquisition of Assets [Abstract]

Schedule of Total Consideration Paid

The total consideration paid was $51.6 million and consisted of:

(in thousands, except share data)
Fair value of 4,589,771 Aquinox common stock	$	15,055
Fair value of 101,927 Aquinox convertible preferred stock		33,432
Cash consideration for fractional shares		5
Transaction costs		3,086
Total consideration	$	51,578

Summary of the Assets Acquired and Liabilities Assumed

The following table summarizes the assets acquired and liabilities assumed:

(in thousands)
Assets acquired:
Cash and cash equivalents	$	3,282
Receivables, prepayments and deposits		560
Property and equipment		1,034
In-process research and development		47,716
Intangible asset		659
Total assets acquired		53,251
Liabilities assumed:
Accounts payable and other liabilities		1,472
Financing lease liability		201
Total liabilities assumed		1,673
Total consideration	$	51,578